Gregor Verhoef
About
Gregor Verhoef is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology.
According to data from OpenAlex, Gregor Verhoef has authored 187 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Pathology and Forensic Medicine, 62 papers in Genetics and 62 papers in Oncology. Recurrent topics in Gregor Verhoef's work include Lymphoma Diagnosis and Treatment (93 papers), Chronic Lymphocytic Leukemia Research (53 papers) and Acute Myeloid Leukemia Research (35 papers). Gregor Verhoef is often cited by papers focused on Lymphoma Diagnosis and Treatment (93 papers), Chronic Lymphocytic Leukemia Research (53 papers) and Acute Myeloid Leukemia Research (35 papers). Gregor Verhoef collaborates with scholars based in Belgium, United States and Netherlands. Gregor Verhoef's co-authors include Peter Vandenberghe, Marc Boogaerts, Johan Maertens, Sigrid Stroobants, Iwona Włodarska, Karoline Spaepen, Bob Löwenberg, Gert J. Ossenkoppele, José Thomas and Edo Vellenga and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Nature Genetics.
In The Last Decade
Gregor Verhoef
186 papers receiving 9.2k citations
Hit Papers
Author Peers
Peers are selected by citation overlap in the author's most active subfields. citations · hero ref
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Gregor Verhoef | 3.5k | 3.1k | 3.0k | 2.3k | 2.2k | 187 | 9.4k | |
| André Bosly | 5.8k 1.7× | 2.0k 0.6× | 4.8k 1.6× | 2.4k 1.1× | 1.4k 0.6× | 191 | 9.7k | |
| Marco Bregni | 3.0k 0.9× | 3.8k 1.2× | 4.7k 1.5× | 1.6k 0.7× | 2.0k 0.9× | 193 | 10.0k | |
| Patrick J. Stiff | 2.3k 0.7× | 3.2k 1.0× | 4.1k 1.4× | 1.2k 0.6× | 1.4k 0.6× | 247 | 8.4k | |
| Anna Sureda | 4.5k 1.3× | 5.0k 1.6× | 5.6k 1.8× | 2.3k 1.0× | 1.5k 0.7× | 465 | 11.7k | |
| Marinus H. J. van Oers | 2.8k 0.8× | 1.7k 0.6× | 2.8k 0.9× | 2.4k 1.1× | 1.9k 0.9× | 175 | 9.0k | |
| Jiřı́ Mayer | 2.6k 0.7× | 4.0k 1.3× | 1.7k 0.5× | 4.7k 2.1× | 1.6k 0.8× | 421 | 8.7k | |
| Hanneke C. Kluin‐Nelemans | 6.5k 1.9× | 3.2k 1.0× | 4.5k 1.5× | 4.2k 1.8× | 2.1k 1.0× | 376 | 14.0k | |
| Ajay K. Gopal | 4.4k 1.2× | 1.6k 0.5× | 5.3k 1.8× | 1.5k 0.7× | 1.4k 0.7× | 391 | 11.5k | |
| Alberto Bosi | 1.5k 0.4× | 6.1k 2.0× | 2.3k 0.7× | 3.6k 1.6× | 2.3k 1.1× | 321 | 10.5k | |
| Nöel Milpied | 4.2k 1.2× | 6.1k 2.0× | 5.3k 1.7× | 2.8k 1.2× | 1.7k 0.8× | 423 | 13.9k |
Countries citing papers authored by Gregor Verhoef
Since
Specialization
Citations
This map shows the geographic impact of Gregor Verhoef's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregor Verhoef with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregor Verhoef more than expected).
Fields of papers citing papers by Gregor Verhoef
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Gregor Verhoef. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregor Verhoef. The network helps show where Gregor Verhoef may publish in the future.
Co-authorship network of co-authors of Gregor Verhoef
This figure shows the co-authorship network connecting the top 25 collaborators of Gregor Verhoef. A scholar is included among the top collaborators of Gregor Verhoef based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregor Verhoef. Gregor Verhoef is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Verhoef, Gregor, Ann Janssens, Feng Jung Sherida H. Woei-A-Jin, et al.. (2022). [18F]FDG-PET/CT volumetric parameters can predict outcome in untreated mantle cell lymphoma. Leukemia & lymphoma. 64(1). 161–170.
2.
Debackere, Koen, Lukas Marcelis, Sofie Demeyer, et al.. (2021). Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified. Nature Communications. 12(1). 3705–3705.
3.
Agazzi, Giorgio Maria, Frederik De Keyzer, Olivier Gheysens, et al.. (2021). Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome. Radiology Imaging Cancer. 3(2). e200061–e200061.
4.
Knoops, L., Gregor Verhoef, Z. N. Berneman, et al.. (2016). Real-world data from 54 Belgian patients from the ponatinib named patient programme (NPP). Ghent University Academic Bibliography (Ghent University).
5.
Dierickx, Daan, Gregor Verhoef, Paul M. Clément, et al.. (2014). Characteristics, treatment and prognosis of primary central nervous system lymphoma: a single center retrospective study. Acta Clinica Belgica. 69.
6.
Fayad, Luis, Fritz Offner, Mitchell R. Smith, et al.. (2013). Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. Journal of Clinical Oncology. 31(5). 573–583.
7.
Wolter, Pascal, et al.. (2013). Physical Activity and Risk of Lymphoma: A Meta-Analysis. Cancer Epidemiology Biomarkers & Prevention. 22(7). 1173–1184.
8.
Advani, Anjali S., Bertrand Coiffier, Myron S. Czuczman, et al.. (2010). Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. Journal of Clinical Oncology. 28(12). 2085–2093.
9.
Verhoef, Gregor, Mitchell R. Smith, Peter Johnson, et al.. (2010). Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity in patients with relapsed/refractory follicular or 'aggressive' lymphoma. Ghent University Academic Bibliography (Ghent University).
10.
Cornelissen, Jan J., Bronno van der Holt, Gregor Verhoef, et al.. (2008). Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood. 113(6). 1375–1382.
11.
Beel, Andrew J., Bartosz Wasąg, Jan Cools, et al.. (2008). Flow cytometric analysis of oncogenic signal transduction pathways in primary leukaemic cells. Haematologica. 93. 223–224.
12.
Dierickx, Daan, Ann Janssens, Gregor Verhoef, et al.. (2007). Rituximab therapy for immune-mediated hematological disorders: A Belgian multi-center project. Acta Clinica Belgica. 62(4). 255–255.
13.
Ossenkoppele, G. J., Wilfried J. Graveland, Pieter Sonneveld, et al.. (2002). Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood. 100(11).
14.
Ossenkoppele, GJ, Bronno van der Holt, Pieter Sonneveld, et al.. (2001). A randomized study on the value of Fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. A report from the Dutch-Belgian hemato-oncology cooperative group (HOVON). Blood. 98(11).
15.
Spaepen, Karoline, Sigrid Stroobants, Patrick Dupont, et al.. (2001). Early restaging positron emmision tomography (PET) with 18F-fluorodeoxyglucose ((18)FDG) predicts outcome in patients with aggressive non Hodgkin's lymphoma (NHL).. Blood. 98(11).
16.
Vandenberghe, Peter, H Demuynck, Gregor Verhoef, et al.. (1998). Intensive non-myeloablative chemotherapy can induce GvHD and complete remission in patients with AML/MDS relapsing after allo-BMT. British Journal of Haematology. 102(1). 210–210.
17.
Maertens, J., H Demuynck, Gregor Verhoef, et al.. (1996). Granulocyte-macrophage colony-stimulating factor (GM-CSF) fails to improve outcome in invasive fungal infections in neutropenic cancer patients. Blood. 88(10). 3274–3274.
18.
Demuynck, H, Gregor Verhoef, Johan Maertens, et al.. (1996). Intensive chemotherapy followed by autologous progenitor cell transplantation may lead to prolonged hematological and molecular remission in chronic lymphocytic leukemia (CLL). Blood. 88(10). 488–488.
19.
Stroobants, Sigrid, Patrick Dupont, Gregor Verhoef, et al.. (1996). Comparison of whole-body positron emission tomography and Gallium-67 citrate imaging for staging of lymphoma. Blood. 88(10). 901–901.
20.
Daenen, Simon, Bob Löwenberg, Pieter Sonneveld, et al.. (1994). Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).. PubMed. 8(1). 6–10.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by André Bosly Breakdown of academic impact, for papers by Marco Bregni Breakdown of academic impact, for papers by Patrick J. Stiff Breakdown of academic impact, for papers by Anna Sureda Breakdown of academic impact, for papers by Marinus H. J. van Oers Breakdown of academic impact, for papers by Jiřı́ Mayer Breakdown of academic impact, for papers by Hanneke C. Kluin‐Nelemans Breakdown of academic impact, for papers by Ajay K. Gopal Breakdown of academic impact, for papers by Alberto Bosi Breakdown of academic impact, for papers by Nöel Milpied